Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmanex

Quick Facts

Property	Description
Active Ingredient	Mometasone Furoate
Primary Form	Inhalation Powder / Inhalation Aerosol (DPI / MDI)
Pharmacological Class	Inhaled Corticosteroid (ICS)
General Purpose	Long-term Maintenance Treatment
Origin	Synthetic Glucocorticoid

The Pharmacological Identity of Asmanex

Asmanex is an inhalation medicine whose active ingredient is Mometasone Furoate, a potent, synthetic compound classified as a glucocorticoid. This medication falls under the pharmacological class of Inhaled Corticosteroids (ICS), and its fundamental purpose is to serve as a maintenance treatment, or prophylactic therapy, for chronic respiratory inflammation. Mometasone Furoate is clinically recognized for its strong topical anti-inflammatory efficacy and low systemic bioavailability, minimizing systemic exposure while acting locally in the lungs. This means the drug is designed for sustained, consistent use to manage underlying issues, such as reducing the swelling that makes airways sensitive over time, rather than for the rapid treatment of sudden breathing episodes. It is exclusively a prescription-only product.

Mometasone Furoate Delivery Systems and Forms

The effective function of this drug relies on its direct application via oral inhalation, ensuring the Mometasone Furoate targets the airways locally. The medication is supplied in two specific dosage forms: the original Dry Powder Inhaler (DPI), and the Metered Dose Inhaler (MDI), which delivers an aerosol suspension. This class of corticosteroid is characterized by its potent anti-inflammatory properties and its localized delivery mechanism. The availability of both a powder-based system and a propellant-based system offers clinicians and patients flexibility, ensuring the optimal administration technique can be selected based on the user's specific inhalation capabilities. This single-component medication is suitable for long-term airway stability in both adult and appropriate pediatric patient groups.

Regulatory References

What side effects are possible with Asmanex?

Possible Side Effects and Safety Information

The following safety information for Asmanex (mometasone furoate inhalation powder) is strictly based on data documented in official governmental regulatory sources.

Documented Adverse Reactions

Side effects are categorized by frequency and the body system affected, according to established regulatory standards:

Classification	Examples of Reactions
Most Common	Headache, Pharyngitis (sore throat), Sinusitis, Upper Respiratory Tract Infection, Oral Candidiasis (thrush).
System-Organ Classes	Infections, Immune System Disorders, Nervous System Disorders, Respiratory Disorders, Eye Disorders, Endocrine Disorders.

Serious and Systemic Safety Risks

Although rare, certain clinically significant reactions are documented in the official labeling:

Adrenal Suppression: This is a systemic risk where the medicine may affect the body's ability to produce natural corticosteroid hormones, particularly during periods of stress or when switching from oral steroids. This can lead to potentially life-threatening Adrenal Insufficiency.
Paradoxical Bronchospasm: An immediate, unexpected worsening of breathing and wheezing right after using the inhaler.
Ocular Effects: Prolonged use may contribute to the development of Cataracts or Glaucoma.
Allergic Reactions: Serious hypersensitivity reactions, including Anaphylaxis and Angioedema, have been reported.

Population-Specific and Use-Related Constraints

Official documents outline specific safety considerations:

Pediatrics: Monitoring of growth velocity is required for children and adolescents receiving treatment.
Duration/Dose: The risk of systemic effects like Bone Mineral Density loss is associated with high doses or long-term use.
Limitations: This medicine is not indicated for the treatment of acute, severe asthma episodes or Status Asthmaticus. Caution is advised for use in patients with untreated or active infections, such as tuberculosis.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mometasone Furoate inhalation overdose defines risks across acute and chronic exposure. Acute overdose from a single excessive inhalation is generally classified as unlikely to be serious and often requires no more treatment than observation.

Manifestation Type	Documented Presentations
Chronic Overdose	Hypercorticism (signs of excess systemic steroid) and HPA axis suppression, which is suppression of the body's natural steroid function.
Severe Outcome	Adrenal insufficiency, a potentially life-threatening complication of chronic HPA suppression.
Acute Symptoms	Serious allergic reactions (e.g., swelling of the face, tongue, or breathing problems) and paradoxical bronchospasm.

Mandated Emergency Actions

Patients must seek immediate medical care when experiencing signs of a serious allergic reaction, as required by regulatory instructions. In this acute situation, the product must be immediately discontinued. If chronic hypercorticism is suspected, the regulatory instruction is for the medication to be discontinued slowly and for the patient to receive symptomatic and supportive treatment. No specific antidote is known for Mometasone Furoate overdose. The systemic effects of long-term high-dose exposure may lead to growth retardation in pediatric patients.

Therapeutic Uses of Asmanex

What Asmanex Treats: Main Uses and Benefits

Asmanex (Mometasone Furoate) is a controller medicine used for the long-term management of asthma across relevant patient groups. It is indicated for use where additional symptomatic support is needed, particularly in contexts involving long-term symptomatic management.

This medication is relevant in conditions characterized by periods of heightened symptoms, specifically persistent asthma. It helps address symptom clusters that may become intense or disruptive, such as recurrent wheezing, chest tightness, and chronic asthma-related coughing. This medication is used in situations where symptoms are related to inflammatory or irritative states.

It is utilized across conditions presenting with recurrent or episodic manifestations and is relevant for managing symptoms that interfere with daily comfort. The core benefit is found in addressing symptomatic discomfort and helping with symptoms that become more disruptive during flare-ups, contributing to improved day-to-day comfort.

Quick Fact: Support for Symptoms that Interfere with Daily Functioning
Primary Goal: Assists with maintaining functional stability.
Symptom Type: Relevant in conditions involving episodic or fluctuating manifestations.
Use Context: Applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

NIH DailyMed prescribing information

Eligibility and Restrictions for Use

The official regulatory profile for Asmanex (mometasone furoate) defines specific population rules regarding its use for the maintenance treatment of asthma.

Eligibility Scope	Regulatory Status
Acute Symptoms	Contraindicated for status asthmaticus or acute episodes; it is not a rescue inhaler.
Hypersensitivity	Contraindicated with known allergy to mometasone furoate or any product ingredients.
Milk Protein Allergy	The Twisthaler device is contraindicated due to the inclusion of milk proteins in the formulation.
Pediatric Use	Approved for the Twisthaler from 4 years of age and the HFA/MDI from 5 years of age. Use is not established for children below these respective minimum ages.

Eligibility-Related Restrictions

Official labeling requires caution in specific populations. This includes patients with underlying infections, such as tuberculosis or untreated systemic fungal, bacterial, or viral infections. Close monitoring is also necessary for patients who are transitioning from systemic (oral) corticosteroids due to the risk of adrenal function impairment. For pregnancy and lactation, limited clinical data are available; use requires a clinical risk-benefit assessment, and infants of exposed mothers should be monitored for signs of hypoadrenalism.

What should I know about interactions with other medicines?

Asmanex's interaction profile is primarily defined by the way its active ingredient, Mometasone Furoate, is processed by the body. The drug is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Any substance that inhibits this metabolic pathway can alter the systemic exposure of Mometasone Furoate. The official regulatory documents identify a significant pharmacokinetic interaction with strong CYP3A4 inhibitors.

Documented Interaction Patterns

Interaction Classification	Official Statement
Metabolic Inhibition	Co-administration with strong CYP3A4 inhibitors, such as Ritonavir or Cobicistat, can inhibit the metabolism of Mometasone Furoate.
Exposure Outcome	Inhibition leads to an increase in systemic exposure and raises the risk of increased systemic corticosteroid effects.
Co-administration Guidance	Co-treatment should be undertaken with caution or avoided unless the potential benefit outweighs the increased systemic risk.
Population Consideration	Hepatic impairment is a factor where reduced drug clearance leads to increased systemic exposure.

The drug's official labeling does not include specific constraints for co-administration timing, nor does it list specific interactions with common foods, alcohol, or herbal products. The entire interaction structure is focused on the impact of enzyme inhibition and subsequent modification of systemic drug levels.

Mechanism of Action

Molecular Targeting and Genomic Regulation

The mechanism of Mometasone Furoate begins with its action as a high-affinity agonist of the Glucocorticoid Receptor (GR), a protein found inside airway cells. The activated drug-receptor complex translocates to the cell nucleus, where it engages in genomic regulation. This process directly modulates gene transcription, leading to the transrepression of pro-inflammatory transcription factors, such as NF-kappaB, while simultaneously enhancing the synthesis of anti-inflammatory proteins, such as Annexin A1.

Suppression of Inflammatory Cascades and Cellular Activity

This genomic regulation modifies signaling sequences by diminishing the synthesis of key inflammatory mediators, including certain interleukins (e.g., IL-4, IL-5) and components of the arachidonic acid cascade. This suppresses the cellular activity and infiltration of cells like eosinophils and mast cells, which drive chronic inflammation. The resultant physiological effect is a reduction in local capillary permeability and decreased fluid leakage, leading to long-term modulation of airway tissue structure and diminished edema. The overall reduction in inflammation reduces the physiological hyperreactivity of the airway tissue.

⏳ Mechanism Constraints: Dependence on Protein Synthesis

The fundamental reliance of this mechanism on gene expression and protein synthesis means its action is time-dependent. Full physiological pathway modulation requires the cumulative molecular effect to manifest over a period of days to weeks. Consequently, the delayed onset mechanism is insufficient to reverse immediate, acute changes in airway smooth muscle tone.

Dosage and Administration Information

How to use Asmanex: Official Administration Guidelines

Asmanex (Mometasone Furoate) is prescribed exclusively for maintenance treatment and is administered via oral inhalation only. It is not intended for the rapid relief of acute symptoms, requiring a separate short-acting inhaler for such episodes. Administration involves using either a Dry Powder Inhaler (DPI) or a Metered Dose Inhaler (MDI), with specific dosage schedules.

Labeled Dosing and Administration Patterns

Administration Principle	Official Usage Description
Route of Administration	Strictly Oral Inhalation only.
Frequency Pattern	Typically used once daily (often in the evening) or twice daily (morning and evening).
Adult Dosing Ranges	Starting and maintenance doses range generally from 200 mu g to 400 mu g total daily, with a maximum dose of up to 800 mu g daily (MDI) or 880 mu g daily (DPI) depending on the patient's prior therapy.
Pediatric Dosing	Specific lower doses are established for children. For example, the DPI is dosed at 110 mu g once daily for children aged 4 to 11 years.

Administration Procedure and Long-Term Use

Administration requires specific procedural steps. Patients using the MDI must prime the device before initial use or if it has been unused for several days. A key instruction is that patients must rinse their mouth with water and spit out the contents immediately following each use to complete the procedure.

Asmanex is utilized as part of a long-term plan. Once the desired level of control is achieved, the prescribing protocol requires that the dose be gradually reduced (titrated) to the lowest effective dosage to maintain stability. Full therapeutic benefit requires regular, consistent use and may not be realized until after one week or longer of continuous treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asmanex

Evidence for Use in Maintenance Treatment of Persistent Asthma

Official regulatory research into Mometasone Furoate (the active ingredient in Asmanex) was conducted to evaluate its use as a long-term maintenance treatment for asthma. Official research records primarily reference Randomized Controlled Trials (RCTs). In these trials, patients with persistent asthma were assigned at random to receive Mometasone Furoate or a non-active placebo, allowing researchers to explore how symptoms change over defined time intervals. These studies were generally conducted over short- to intermediate-term periods, typically lasting between 12 and 26 weeks.

Types of Outcomes Measured in Clinical Trials

Research focused on conditions marked by functional limitations and where symptoms may vary in intensity. Research examined key functional endpoints like Forced Expiratory Volume in 1 Second ( FEV1) and Peak Expiratory Flow ( PEF). Clinical studies also monitored the frequency of episodic or acute changes. This included tracking asthma exacerbation events (or flare-ups) and recording the number of times patients reported using their short-acting beta2-agonist rescue inhaler.

Evidence in Specific Patient Groups

Mometasone Furoate was evaluated in large groups of adults and adolescents (those aged 12 and older). For these groups, multiple RCTs reported similar patterns regarding primary outcomes. Separate, dedicated research studies also explored the use of Mometasone Furoate for children, typically in the 4 to 11 age range, with persistent asthma.

Key Uncertainties and Research Limitations

While the research base for short-term outcomes in adults is substantial, limitations exist. The primary evidence base focusing on clinical effects primarily involves studies with follow-up durations that were limited (6 months or less). Additionally, comparative evidence remains limited because there is not a large volume of direct, randomized head-to-head trials comparing Mometasone Furoate monotherapy against every other available inhaled corticosteroid across all studied doses. Research does not determine whether an individual will respond similarly to the patterns observed in the studied populations.

Key Studies & References

Clinical Review Report: Indacaterol/Mometasone Furoate (Atectura Breezhaler) - Overview of Clinical Evidence (Includes discussion of Mometasone Furoate monotherapy trials)

How should Asmanex be stored and disposed of?

Storing and Disposing of Asmanex (Mometasone Furoate)

Asmanex must be stored according to regulatory specifications to ensure stability, and all forms must be kept out of the reach of children.

Official Storage Conditions

Item	Requirement (HFA / Twisthaler)
Temperature	Controlled room temperature (68^\circF to 77^\circF or 20^\circC to 25^\circC).
Prohibitions	Protect from freezing (both forms) and refrigeration (Twisthaler).
Container	Asmanex HFA canister must be stored with the mouthpiece down.
Protection	Twisthaler must remain in its original packaging prior to use to protect from moisture.

Stability and Disposal Rules

Asmanex HFA must be discarded when the dose counter reads "000." The Asmanex Twisthaler is to be discarded three months after its foil pouch is opened, or when the dose counter reaches zero. Due to its pressurized nature, the HFA canister must not be punctured, exposed to high heat (above 120^\circF / 49^\circC), or incinerated. Disposal of all unused product and waste material must comply with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.